Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-RTS-hIL-12 + Veledimex + Cemiplimab in Recurrent Glioblastoma
NCT04006119Phase 2Terminated
- Sponsor
- Alaunos Therapeutics
- Start
- Aug 2019
- Primary completion
- Aug 2021
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ad-rts-hil-12 in glioblastoma (GBM), sponsored by Alaunos Therapeutics. Primary endpoints: Safety of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex in Combination With Cemiplimab-rwlc at 2 years and Efficacy of Intratumoral Ad-RTS-hIL-12 and Oral Veledimex in Combination With Cemiplimab-rwlc at 2 years. Started Aug 2019; status: terminated.
02
Drugs
ad-rts-hil-12
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04006119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006119.